U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
The U.S. FDA has approved BRAFTOVI (encorafenib) in combination with cetuximab and mFOLFOX6 for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. This indication is approved under accelerated approval based on response rate and durability of response. Was this helpful? Yes No What are the benefits of the BRAFTOVI combination regimen for patients with metastatic colorectal cancer with a BRAF V600E mutation? The BRAFTOVI combination regimen has demonstrated high response rates that are rapid and durable, representing an encouraging sign of continued disease control and a source of renewed hope for patients. The median duration of response (DoR) was 13.9 months for the BRAFTOVI combination regimen versus 11.1 months for chemotherapy, with or without bevacizumab. Was this helpful? Yes No What is the prevalence of BRAF mutations in metastatic colorectal cancer? BRAF mutations are estimate
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerBusiness Wire
- Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now? [Yahoo! Finance]Yahoo! Finance
- Why Pfizer (PFE) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
- GoComet's Odyssey Singapore 2024 Highlights: When Supply Chain Giants MeetPR Web
- Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with AnalystsBusiness Wire
PFE
Earnings
- 10/29/24 - Beat
PFE
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 8-K
- PFE's page on the SEC website